These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3805775)

  • 21. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats.
    Fox LE; King RR; Shi F; Kurzman ID; MacEwen EG; Kubilis PS
    Cancer Biother; 1994; 9(4):329-40. PubMed ID: 7719380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.
    Malik ST; Martin D; Hart I; Balkwill F
    Br J Cancer; 1991 Mar; 63(3):399-403. PubMed ID: 2003980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
    Fidler IJ; Fogler WE; Brownbill AF; Schumann G
    J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
    Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
    Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of chemotherapy- or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide.
    Killion JJ; Brown DR; Wilson MR; Lloyd MM; Fidler IJ
    Oncol Res; 1994; 6(8):357-64. PubMed ID: 7894085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.
    MacEwen EG; Kurzman ID; Helfand S; Vail D; London C; Kisseberth W; Rosenthal RC; Fox LE; Keller ET; Obradovich J
    J Drug Target; 1994; 2(5):391-6. PubMed ID: 7704483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
    Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
    J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
    Pahl JH; Kwappenberg KM; Varypataki EM; Santos SJ; Kuijjer ML; Mohamed S; Wijnen JT; van Tol MJ; Cleton-Jansen AM; Egeler RM; Jiskoot W; Lankester AC; Schilham MW
    J Exp Clin Cancer Res; 2014 Mar; 33(1):27. PubMed ID: 24612598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.
    Talmadge JE; Schneider M; Collins M; Phillips H; Herberman RB; Wiltrout RH
    J Immunol; 1985 Aug; 135(2):1477-83. PubMed ID: 4008928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
    Shi F; MacEwen EG; Kurzman ID
    Cancer Res; 1993 Sep; 53(17):3986-91. PubMed ID: 8358727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes.
    Sone S; Tandon P; Utsugi T; Ogawara M; Shimizu E; Nii A; Ogura T
    Int J Cancer; 1986 Oct; 38(4):495-500. PubMed ID: 3093390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens.
    Ullrich SE; Fidler IJ
    J Leukoc Biol; 1992 Nov; 52(5):489-94. PubMed ID: 1431559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
    Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
    J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Liposome-Entrapped Muramyl Tripeptide Phosphatidylethanolamine (L-MTP-PE) on the Tumor Growth and Survival of Mice Bearing Syngeneic Tumor in Combination with a Chemotherapeutic or Immunomodulatory Agent.
    Tanaka M; Abe S
    Drug Res (Stuttg); 2022 Sep; 72(7):372-377. PubMed ID: 35767993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of experimental endotoxin shock by a monocyte activator.
    Passlick B; Labeta MO; Izbicki JR; Ostertag P; Löffler T; Siebeck M; Pichlmeier U; Schweiberer L; Ziegler-Heitbrock HW
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2535-40. PubMed ID: 8585740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.
    Meyers PA
    Adv Exp Med Biol; 2020; 1257():133-139. PubMed ID: 32483736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative studies of cytotoxicity and the release of TNF-alpha, nitric oxide, and eicosanoids of liver macrophages treated with lipopolysaccharide and liposome-encapsulated MTP-PE.
    Dieter P; Ambs P; Fitzke E; Hidaka H; Hoffmann R; Schwende H
    J Immunol; 1995 Sep; 155(5):2595-604. PubMed ID: 7650390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disposition of antigen-presenting liposomes in vivo: effect on presentation of herpes simplex virus antigen rgD.
    Ho RJ; Burke RL; Merigan TC
    Vaccine; 1994; 12(3):235-42. PubMed ID: 8165856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
    Meyers PA; Chou AJ
    Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.